Navigation Links
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Date:8/27/2007

y anti-apoptotic proteins such as XIAP. Loss of activity of these proteins restores the ability of chemoresistant tumour cells to undergo apoptosis in response to chemotherapy. The putative molecular target for phenoxodiol is a tumour-specific protein, accounting for the highly selective nature of the drug.

About Marshall Edwards, Inc.: Marshall Edwards, Inc. (Nasdaq: MSHL) is a specialist oncology company focused on the clinical development of novel anti- cancer therapeutics. These derive from a flavonoid technology platform which has generated a number of novel compounds characterised by broad ranging efficacy against a range of cancer targets with few side effects. The unique combination of efficacy and safety has been explained by their ability to target an enzyme present on the surface of cancer cells, thereby inhibiting the production of pro-survival proteins within the cell. Marshall Edwards, Inc., has licensed rights from Novogen Limited (ASX: Novogen - Nasdaq: NVGN) to bring three oncology drugs - phenoxodiol, NV-196 and NV-143 - to market globally. Marshall Edwards, Inc., is majority owned by Novogen, an Australian biotechnology company that is specialising in the development of therapeutics based on a flavonoid technology platform. Novogen, based in Sydney, Australia, is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases. More information on phenoxodiol and on the Novogen group of companies can be found at and http://www.novogen.com .

(1) Piura B and Meirovitz M. Weekly single-agent carboplatin in heavily

pretreated patients with recurrent ovarian, peritoneal and fallopian


'/>"/>

SOURCE Novogen Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... Board of Directors has authorized the implementation of a 1:25 ... be completed on or before January 15, 2012. ... by the Company,s stockholders at a November 4, 2011, special ...
... EXTON, Pa., Jan. 3, 2012 ViroPharma Incorporated (Nasdaq: ... Julie H. McHugh to its board of directors. ... health care industry experience and leadership to ViroPharma,s Board ... of Endo Pharmaceuticals, a U.S.-based, specialty healthcare solutions company.  ...
Cached Medicine Technology:Radient Pharmaceuticals Announces Reverse Stock Split 2ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors 2
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... , ... LLP (ENTA) announced today that it has expanded the implementation of its state-of-the-art Electronic Medical ... City, Long Island, Westchester, Rockland, Putnam and Orange Counties and northern New Jersey. All of ... ...
... ... Department of Corrections , ... Miami, FL (PRWEB) July 1, 2010 -- JPay.com, the Trusted Leader in ... million offenders nationwide with absolutely no cost to correctional departments and today announced the ...
... ... the release of their new Alpha 3C™ formula, designed to naturally support focus, ... ... provider of premium dietary supplements, announces the release of their new Alpha 3C™ ...
... that older adults commonly have low vitamin D levels and ... the metabolic syndrome, a condition that affects one in four ... Annual Meeting in San Diego. "Because the metabolic syndrome ... vitamin D level in the body might be important in ...
... men with higher testosterone levels are more likely to ... the future. The results were presented at The Endocrine ... study finding contradicts smaller studies that have shown that ... cardiovascular disease," said presenting author Kristen Sueoka, MD, a ...
... ... Marijuana emerges as the most popular plant in the United States we,re still ... Casias is a perfect example of the discrimination as at the young age ... been forced to fight Wal-Mart after losing his job for using medicinal marijuana ...
Cached Medicine News:Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 2Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 3Health News:JPay, the Apple of Washington State DOC's eye 2Health News:Purity Products Releases Alpha 3C 2Health News:Low vitamin D linked to the metabolic syndrome in elderly people 2Health News:Higher testosterone may raise risk of heart disease in elderly men 2Health News:Fired Wal-Mart Employee Accepts Full Scholarship to The Medical Marijuana Academy 2
... O.R. Special Protective Apron is made ... and a sterile gown. Uniquely it ... sterile field. Reaching through the back ... are released, and the protective apron ...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... coat apron, weight is distributed uniformly ... comfortable wear without fatigue. Made to ... front closing special procedure apron comes ... that make it a cinch to ...
... Wolfs Easy Wrap Apron has always ... easy to put-on, adjust and take-off. Our ... new Easy sures Wrap features two velcro ... The attached Thyroid collar adjusted to fully ...
Medicine Products: